1. A PHASE I STUDY OF UTOMILUMAB (PF‐05082566), A 4‐1BB/CD137 AGONIST, IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH CD20+ NON‐HODGKIN'S LYMPHOMA. (June 2017) Authors: Gopal, A.; Levy, R.; Houot, R.; Patel, S.; Hatake, K.; Popplewell, L.; Chen, Y.; Davis, C.; Huang, B.; Cesari, R.; Thall, A.; Woolfson, A.; Bartlett, N. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Abnormalities in chromosome 6q24 as a cause of early‐onset, non‐obese, non‐autoimmune diabetes mellitus without history of neonatal diabetes. Issue 7 (11th April 2015) Authors: Yorifuji, T.; Matsubara, K.; Sakakibara, A.; Hashimoto, Y.; Kawakita, R.; Hosokawa, Y.; Fujimaru, R.; Murakami, A.; Tamagawa, N.; Hatake, K.; Nagasaka, H.; Suzuki, J.; Urakami, T.; Izawa, M.; Kagami, M. Journal: Diabetic medicine Issue: Volume 32:Issue 7(2015:Jul.) Page Start: 963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Establishment of optimized ELISA system specific for HLA‐G in body fluids. (31st October 2016) Authors: Ouji‐Sageshima, N.; Geraghty, D. E.; Ishitani, A.; Hatake, K.; Ito, T. Journal: HLA Issue: Volume 88:Number 6(2016) Page Start: 293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Low absolute peripheral blood CD4+ T‐cell count predicts poor prognosis in R‐CHOP–treated patients with diffuse large B‐cell lymphoma. (June 2017) Authors: Kusano, Y.; Yokoyama, M.; Terui, Y.; Hatake, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Negative impact of zoledronic acid in R‐CHOP treated DLBCL with bone metastasis. (June 2017) Authors: Inoue, N.; Nishimura, N.; Takahashi, A.; Kusano, Y.; Yamauchi, H.; Ueda, K.; Mishima, Y.; Yokoyama, M.; Terui, Y.; Tsuyama, N.; Takeuchi, K.; Hatake, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. ONO‐4059 (GS‐4059), A NEXT GENERATION BTK INHIBITOR, MONOTHERAPY IN PATIENTS WITH B‐CELL MALIGNANCIES IN THE JAPANESE PHASE 1, DOSE‐ESCALATION STUDY. (June 2017) Authors: Ando, K.; Hatake, K.; Fukuhara, N.; Kinoshita, T.; Munakata, W.; Shirasugi, Y.; Yokoyama, M.; Ichikawa, S.; Fukuhara, S.; Ohmachi, K.; Tobinai, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 407 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PRETREATMENT SOLUBLE INTERLEUKIN‐2 RECEPTOR LEVEL WAS A ROBUST PROGNOSTIC FACTOR IN FOLLICULAR LYMPHOMA IN RITUXIMAB ERA. (June 2017) Authors: Kusano, Y.; Yokoyama, M.; Terui, Y.; Hatake, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Quantitative analysis of MYD88 L265P mutations by digital PCR is an independent prognostic factor for CNS relapse as well as systemic relapse and poor outcome. (June 2017) Authors: Nishimura, N.; Asaka, R.; Takeuchi, K.; Tsuyama, N.; Inoue, N.; Takahashi, A.; Yamauchi, H.; Kusano, Y.; Ueda, K.; Mishima, Y.; Yokoyama, M.; Terui, Y.; Hatake, K. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 277 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗